German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

Biontech Se Sponsored Adr ( (BNTX)) has released its Q3 earnings. Here is a breakdown of the information Biontech Se Sponsored Adr presented to its investors. BioNTech SE, a cutting-edge global ...

BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...

BioNTech's Q3 revenue surged to €1.244 billion, reflecting early COVID-19 vaccine approvals. Net profit rose to €198.1 million, and full-year guidance adjusted downward.

BioNTech's oncology assets, including BNT327/PM8002, show promising results, with a notable 39.3% ORR in PD-L1-negative EGFR-mutated NSCLC patients. BioNTech's stock has risen by 24% since March ...

Sen. Rand Paul pointed to CDC guidance on child COVID-19 vaccinations, suggesting that people are "hesitant to believe" the ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...